Ryan Drake, DO
Neurology · Canton, OHNPI 1326256462
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $267,078 of the $349,762 with a category attached, or 76.4%. 60 manufacturers reported payments, led by Lilly USA, LLC at 30.9% of the total. 2025 is the largest year on record at $89,483, 2.8 times the $31,681 reported in 2019. Among neurology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,011 payments — averaging $173.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$108K
- AstraZeneca$88K
- Teva Pharmaceuticals USA, Inc.$57K
- SK Life Science, Inc.$36K
- Neurocrine Biosciences, Inc.$16K
- UCB, Inc.$8K
- plus $37K from 54 others
Across 546 payments — averaging $9504.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.8M
- Eisai Inc.$473K
- Alkermes, Inc.$201K
- Avadel CNS Pharmaceuticals, LLC$166K
- Harmony Biosciences LLC$100K
- Novartis$59K
- plus $390K from 20 others
What the payments were for
- Consulting fees$13,4634%
- Speaking & faculty fees$267,07876%
- Travel & lodging$32,5369%
- Food & beverage$35,08310%
- Education$1,6020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$349,762 in reported general payments places this provider in the 95th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 24 | $271,693 |
| Austedo XrDeutetrabenazine | 22 | $165,325 |
| BotoxOnabotulinumtoxina | 86 | $113,060 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $107,514 |
| AustedoDeutetrabenazine | 18 | $104,802 |
| BriviactBrivaracetam | 44 | $87,312 |
| Nurtec OdtRimegepant Sulfate | 57 | $75,591 |
| Aimovig AutoinjectorErenumab-Aooe | 62 | $51,624 |
| QuliptaAtogepant | 34 | $42,393 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 39 | $36,924 |
| AptiomEslicarbazepine Acetate | 20 | $35,367 |
| Emgality PenGalcanezumab-Gnlm | 39 | $33,238 |
| XcopriCenobamate | 26 | $29,687 |
| UbrelvyUbrogepant | 18 | $18,513 |
| OngentysOpicapone | 24 | $16,193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $15,551 | $287,88748 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $57,339 | $270,12740 claims |
| AbbVieBotox, Qulipta, Ubrelvy | $3,378 | $173,966138 claims |
| UCB, Inc.Briviact | $8,098 | $87,31244 claims |
| PfizerNurtec Odt | $775 | $75,59157 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $271 | $35,36720 claims |
| SK Life Science, Inc.Xcopri | $35,709 | $29,68726 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $1,437 | $8,65289 claims |
| Upsher-smith Laboratories LLCTopiramate | $101 | $1,967184 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 702 neurology providers in Ohio.
Other neurology in Canton
- Andrew StalkerCanton$280K
- Aram ZabetiCincinnati$1.6M
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Martin TaylorNew Albany$821K
- Jacqueline NicholasColumbus$743K
- Lawrence ElmerToledo$687K
- Kenneth PugarCenterville$582K
- Brendan BauerSheffield Village$548K
- Geoffrey EubankColumbus$508K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.